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Background: A territory-wide diabetes management program (Risk Assessment Management Program – RAMP)
was recently established, providing comprehensive management for all diabetics, helping to delineate current level
of control and complications prevalence among primary care diabetic patients in Hong Kong.
Method: This cross-sectional study captured anonymous clinical data from RAMP patients. Data obtained include
sociodemographic details, type of diabetes, illness duration, family history, drug usage, coexisting illnesses, diabetic
complications and other clinical parameters.
Results: Data from 15,856 type 2 diabetic patients were analyzed. 57.1% were above 60 years old, with mean
disease duration of 7.3 years. Hypertension was the commonest coexisting chronic illness (57.6%). 30.2% and 61.8%
have their systolic and diastolic pressure controlled to below 130 mmHg and 80 mmHg respectively. Over half
(51.5%) had an HbA1c level of less than 7.0%. 88.4% did not achieve target lipid level. 15% were on diet control
alone. Only 22.2% were on statins. In patients with microalbuminuria and macroalbuminuria, 40.7% and 54.5% were
on angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) respectively. 12.9%, 38.8%
and 2.4% had diabetic retinopathy, nephropathy and neuropathy respectively. Overall, 37.9%, 7.3% and 0.4% had
single, two and three concurrent microvascular complications respectively.
Conclusion: The level of diabetic control is comparable with other developed countries. We demonstrated a high
prevalence of microvascular complications among Chinese primary care patients despite achieving adequate HbA1c
levels, highlighting the importance of managing all aspects of diabetes including weight, lipid and blood pressure.
Efforts to improve holistic management must be tailored according to the needs of our population, with the
challenges that the majority have low educational background and in the older age group.
Keywords: Diabetic complications, Primary care, Chronic illness, Screening programBackground
According to the latest information from the World Health
Organization, around 346 million people worldwide have
diabetes [1]. Although figures vary with estimation methods
from different organizations [2,3], there is consensus that
the prevalence of diabetes will continue to rise, increasing
the burden to our limited healthcare resources.* Correspondence: philipli@cuhk.edu.hk
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reproduction in any medium, provided the orOver the last few years, Hong Kong’s public primary
care has introduced a new diabetes management service
(Risk Assessment Management Program – RAMP) that
provides comprehensive management for all diabetic
patients, including annual blood tests, and two-yearly
examination for retinopathy, neuropathy and nephropathy.
All information is recorded electronically, allowing
healthcare providers to review patients’ conditions in a
much more effective and efficient way. This has also
enabled healthcare providers to review the level of control
and prevalence of complications among diabetic patients.td. This is an open access article distributed under the terms of the Creative
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have estimated prevalence using previous publications. A
local reference framework for diabetes [4] was established
in 2010, emphasizing the need for a comprehensive
management of diabetes in the primary care setting.
However, there is currently limited primary care data on
the level of control and the prevalence of complications,
which are essential in helping service providers to correctly
allocate healthcare resources. Moreover, extrapolation
from existing data may prove ineffective because of
the substantial variation across different countries, which
in turn is related to differences between populations and
healthcare systems. Data from RAMP therefore provides
an exceptional opportunity to delineate the current level
of control and prevalence of complications among
primary care diabetic patients in Hong Kong.
Method
This study is a cross-sectional study, collecting anonymised
computerized clinical data obtained from RAMP in eight
public primary care clinics of Hong Kong. The public
primary care system in Hong Kong provides service to
patients with chronic illness, as well as socioeconomically
deprived patients with episodic illnesses. Overall these
eight clinics look after around 200,000 patients, amongst
which around 20,000 have diabetes. Only data from
patients’ first visit to RAMP were included. In order to be
eligible for RAMP, patients must have a pre-existing
diagnosis of diabetes. Information obtained in RAMP was
recorded in the computerized Clinical Management
System; patient data were anonymized by the computer
system before they were drawn for analysis.
We obtained information including sociodemographic
details, type of diabetes, duration of diabetes, family
history of diabetes, compliance to treatment (patients’
self-report), drug usage (including both diabetes and
non-diabetes related), presence or absence of coexisting
conditions according to patient’s clinical history and past
medical records (including systemic hypertension, coronary
heart disease, cerebrovascular disease, heart failure, cataract,
glaucoma, erectile dysfunction and claudication), presence
or absence of specific clinical findings (including numbness
and pinprick sensation), foot abnormalities (including
graduated tuning fork test and 10 g monofilament test)
and ankle jerks (performed by trained diabetes nurses).
The following parameters were also retrieved: visual
acuity (using Snellen chart assessment), blood pressure
(measured with electronic sphygmomanometer), body
weight, height, waist hip ratio, HbA1c, lipid profile,
fasting glucose, eGFR (MDRD) and spot urine albumin to
creatinine ratio (uACR) (all tests performed in accredited
government hospitals’ laboratories). Retinal examination
was performed by a trained optometrist using retinal pho-
tography. Two fields of the retina would be photographedfor each eye. One photo was centred at the macula and
the other at the optic disc. A quality assured grading
system with ophthalmologist support was in place to
ensure the retinopathy grading results were accurate.
All photographs were reviewed by a trained optometrist.
Another trained optometrist would act as the secondary
grader for all abnormal retinal photographs and 15%
of the retinal photographs reviewed as normal by the
first optometrist. When there was disagreement, the
ophthalmologist made the final decision.
The definitions used for specific variables are as follows:
1. Retinopathy
a. Mild non-proliferative (NPDR) – microaneurysms
b. Moderate to severe NPDR – microaneurysms and
other microvascular lesions, including venous
beading ≥2 quadrants, or intraretinal
microvascular abnormalities ≥1 quadrant but not
proliferative diabetic retinopathy
c. Proliferative – neovascularisation of optic disc or
elsewhere, preretinal haemorrhage, or vitreous
haemorrhage
2. Nephropathy
a. Overt – uACR >300 mg/g (or > 34 mg/mmol)
b. Incipient nephropathy – uACR 30–300 mg/g
(or 3.4-34 mg/mmol)
c. Normoalbuminuria – normal uACR
(<30 mg/g or <3.4 mg/mmol)
3. Neuropathy - Defined as presence of abnormal
monofilament test or gradated tuning fork test
Statistical analysis
Statistical analysis was performed by SPSS for Windows
version 18.0 (SPSS Inc., Chicago, IL). All data are
expressed as mean ± standard deviation unless otherwise
specified.
Ethical considerations
Application for ethics approval was initially considered
before the start of the study. Nevertheless, taking into
account that all data were drawn in an anonymized
manner, and that data obtained for this study was part
of the RAMP audit process, ethical approval from local
ethics committee was finally considered unnecessary.
Results
Patient demography
From 1 Oct 2009 to 31 Dec 2011, 15,856 diabetic
patients from the eight specified clinics have received
care under RAMP. All were type 2 diabetics. Their
sociodemographic details are shown in Table 1. 57.1%
of the patients were above 60 years old, and 51.2%
were female. The mean duration of diabetes among
Table 1 Sociodemographics of study population
Characteristic
Gender Female 51.2%
Male 48.8%
Age group 20-29 0.1%
30-39 1.1%
40-49 9.2%
50-59 32.4%
60-69 29.4%
70-79 20.7%
80-89 6.8%
>89 0.2%
Smoking status Never-smoked 71.6%
Ever-smoked 28.4%
Alcohol intake Non-drinker 76.1%
Ever-drinker 23.9%
Education level None 18.0%
Primary 40.2%
Secondary 37.0%
Tertiary or above 4.8%
Occupation Housewife 28.8%
Professional 1.9%
Non-manual 10.6%
Manual skilled 10.4%
Manual non-skilled 8.8%
Unemployed 4.3%
Retired 35.2%
Body mass index <18.5 1.2%
18.5-22.9 22.3%
23-24.9 21.9%
25-27.4 26.3%
27.4-30 15.8%
>30 12.4%
Waist hip ratio* Low (<0.8 female; <0.96 male) 25.8%
Moderate (0.81-0.85 female; 0.96-1.0 male) 28.0%
High (>0.85 female; >1.0 male) 46.2%
Home
monitoring
None 62.2%
Urine testing only 1.1%
Finger prick testing 36.3%
Mean duration of diabetes 7.3 years
Comorbidities Hypertension 57.6%
Coronary heart disease 3.8%
Stroke 4.5%
Table 2 Lipid profile and eGFR among study population
Mean blood pressure
Systolic 138 mmHg (18.3)
Diastolic 76 mmHg (10.5)
Mean lipid profile
TC 5.0 mmol/L (0.9)
LDL 3.1 mmol/L (0.8)
HDL 1.2 mmol/L (0.3)
TG 1.6 mmol/L (1.1)
Total cholesterol*
<5.2 60.9%
5.2-6.2 28.8%
>6.2 9.9%
LDL*
<2.6 30.4%
2.6-3.3 35.9%
3.4-4.1 23.2%
4.1-4.9 7.4%
>4.9 2.1%
HDL*
<1.0 16.5%
1.0-1.5 53.6%
>1.5 29.5%
TG*
<1.7 68.1%
1.7-2.2 16.4%
2.3-5.6 14.1%
>5.6 1.0%
Mean eGFR (ml/min/1.73 m2) 84.8 (23.2)
Chronic kidney disease*
Stage 1 38.5%
Stage 2 48.8%
Stage 3 11.7%
Stage 4 0.3%
Stage 5 0.1%
Mean urine ACR 10.2 mg/mmol (42.7)
Proportion normal 67.9%
TC: total cholesterol; LDL: low density lipoprotein; HDL: high density
lipoprotein; TG: triglyceride; ACR: albumin to creatinine ratio.
*Percentages may not add up to 100% because of missing data.
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had education level of primary school or below.
Comorbidities, disease control and drug use
Hypertension was the commonest coexisting chronic
illness in our population (57.6%), while less than 5%
are known to have coronary heart disease and stroke
Mean: 7.2% (SD 1.3)
Figure 1 Distribution of HbA1c values among study population.
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and diastolic blood pressure (DBP) are 138 mmHg
(SD 18.3) and 76 mmHg (SD 10.5) respectively (Table 2)
with a relatively normal distribution (first and third
quartile for SBP being 127 and 151 mmHg, and DBPTable 3 Drug use among study population
Type of therapy Proportion of patients*
Diet alone 15.0%
Glucose lowering therapy
Metformin 64.5%
Sulphonylurea 54.5%
Glitazone 0.5%
Gliptin 0.1%
Insulin 1.6%
Anti-hypertensives
None 35.4%
ACEI or ARB 38.2%
β-blocker 26.6%
CCB 41.8%
Diuretic 13.2%
Lipid lowering therapy
Statin 22.2%
Fibrate 3.7%
Aspirin 9.4%
ACEI: angiotensin converting enzyme inhibitor.
ARB: angiotensin receptor blocker.
CCB: calcium channel blocker.
*Percentages do not add up to 100% because some patients may be taking
more than one therapy.69 and 83 mmHg respectively). Blood pressure control
(below 130/80 mmHg) was achieved in 22.9% and 35.9% of
patients with and without a prior diagnosis of hypertension
respectively (p < 0.001).
In terms of glycaemic control, 51.5% had an HbA1c
level of less than 7.0% (Figure 1). 88.4% of patients did
not achieve target LDL level (2.6 mmol/L) (Table 2).
15% of patients were on diet control alone (Table 3).
39.1% of them are on both a biguanide and sulphonylurea,
while 1.2% are using insulin therapy. Amongst those
taking antihypertensives, 36.6% are on monotherapy,
39.3% on dual therapy, and 24.0% are on three or more.
Only 20.7% of patients are on statins. In patients with
microalbuminuria and macroalbuminuria, 40.7% and
54.5% were on ACEI or ARB respectively.
Prevalence of complications
Table 4 shows the prevalence of complications among our
population. Diabetic retinopathy was detected in 12.9% of
patients. Nephropathy was present in 38.8%. 67.7% had a
urine albumin to creatinine ratio of less than 2.5 mg/mmol
and 3.5 mg/mmol among males and females respectively.
Neuropathy was present in 2.4%. Overall, 37.9%, 6.7% and
0.3% had single, two and three microvascular complications
(among the complications of diabetic retinopathy, nephrop-
athy and neuropathy) respectively (Figure 2). Among male
patients, 15% reported to have erectile dysfunction.
Discussion
This is the first study looking into the epidemiology of
diabetic patients in Hong Kong’s primary care system.
Table 4 Prevalence of diabetic complications
Complication Percentage
Diabetic retinopathy (n = 1920)
Mild non-proliferative 12.1%
Moderate to severe non-proliferative 0.5%
Proliferative 0.3%
Nephropathy (n = 5986)
Incipient 30.9%
Overt 7.9%
Neuropathy (by monofilament/tuning fork) (n = 386) 2.4%
Reported numbness 5.4%
Presence of foot ulcer 0.5%
Absent foot pulses 0.2%
Foot deformity 4.3%
Presence of callosity 30.3%
Presence of suspected skin infection 2.2%
Nail abnormalities 7.3%
Erectile dysfunction (male only) 15.0%
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appears to be comparable with other developed
countries [5,6], with around 50% achieving an HbA1c
of <7.0%. The majority of patients can be controlled with
traditional oral hypoglyaemic agents (OHAs). The
much lower use of gliptins and other newer OHAs is
mainly because these are self finance items in contrast to
traditional medications which are provided without cost,
at the time of the study period (the newer drugs are nowFigure 2 Prevalence of complications among study population.provided according to the guidelines of the Formulary in
Hong Kong). With reference to a previous population
study on hypertension-alone patients [7], the pattern of
antihypertensive drug usage among our diabetic population
is different, with a greater proportion prescribed with an
ACEI or ARB. This is likely to be related to coexisting need
for renal protection among susceptible patients.
Glycaemic control forms only part of the overall
management of diabetes. Despite the well documented evi-
dence on the importance of adequate weight management
[8] as well as blood pressure [9,10] and lipid control
[11-14], gaps currently still exist as evidenced by the large
proportion of patients who are obese, with suboptimal
blood pressure control and abnormal lipid levels. That may
explain partly the reasons for the relatively high prevalence
of incipient and overt nephropathy. Efforts to improve
management must be tailored according to the needs of
our population, where the majority have a low educational
background and a significant proportion being retired and
elderly. Increased resources must also be placed in primary
care so that drug management can be optimized. Currently
although 88.4% have suboptimal lipid levels, only 22.2% are
on statin therapy. ACEIs and ARBs are readily available in
the clinics reviewed in this study. Although practice guide-
lines already exist to help doctors in deciding when these
are required, further education and reminders must be pro-
vided to ensure doctors adhere to evidence-based practice.
Compared with recent primary care literature [15,16],
our study population had a lower prevalence of neuropathy
(2.4% vs >15% in existing literature) and a higher preva-
lence of nephropathy (38.8% vs 10.5%). The prevalence of
retinopathy was comparable. On the other hand, prevalence
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revealed that our primary care patients had a higher rate of
microvascular complications (44.9% vs 34.7%). The reason
for these differences in complication prevalence is unclear.
However, the detection of neuropathy depends on the use
of monofilaments and graduated tuning fork, both of which
is user dependent and subject to patient interpretation. We
could have missed patients with small-fibre damage.
Although we cannot exclude the possibility of underesti-
mating diabetic neuropathy in our program, another cohort
of type 2 diabetes patients from seven Asian countries also
reported a low prevalence of diabetic neuropathy in Hong
Kong (1.9% as compared to the overall prevalence of 15%
in seven countries) [18]. Furthermore, our estimate of
diabetic neuropathy in Chinese patients is concordant with
a recent study in Shanghai reporting a prevalence of
peripheral neuropathy of 8.4% in diabetes subjects [19].
Despite the low insulin usage rate, good average HbA1c
level and short disease duration, our population appears
to have a relatively higher prevalence of microvascular
complication. Primary care physicians must therefore be
aware of this high complication prevalence, educating
patients on the importance of early detection irrespective of
diabetic control. Recently in England, a form of integrated
care, which allowed patients to move seamlessly between
primary, community, and secondary care depending
on need, and which enhanced interaction, information
exchange, and learning across the clinical services was
suggested in order to provide high quality diabetes care
[20]. Such integration actually requires a good knowledge
of the current diabetes care in the different level of
settings. Our data would allow a better review of the
diabetic patients in primary care to enhance further
integration with secondary care.
Limitations of this study include the lack of data on
acute complications and the possibility of selection bias,
where more patients with worse disease control (including
high HbA1c values and those with complications) were
recruited into the program, while others with inadequate
control or multiple comorbidities have been referred to
secondary care. The intention of the program was to in-
clude all diabetic patients irrespective of their current
disease control status. Nevertheless, further data collection
needs to be performed in order to assess whether those
who have not yet entered the program are significantly
different from this study population. Further studies will
also be required in order to see whether our patients with
seemingly milder disease will progress at different rates
from other populations.
Conclusion
This study aimed to obtain a cross-sectional view of the
current level of care among diabetic patients as managed
in the primary care setting. Further data collection willbe required to assess whether this program will have an
impact on diabetic care among our population. More
importantly, data from this study demonstrated a high
prevalence of microvascular complications among
Chinese primary care patients despite achieving adequate
HbA1c levels, highlighting the importance of managing
all aspects of diabetes including weight, lipid and blood
pressure.
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